Yi Yao | Nanomedicine | Best Researcher Award

Published on by ScienceFather

Prof. Yi Yao | Nanomedicine | Best Researcher Award

Renmin Hospital of Wuhan University | China

Prof. Yi Yao is a distinguished oncologist, Ph.D., Chief Physician, and Director of the Cancer Center at Renmin Hospital of Wuhan University, China, with a career dedicated to advancing cancer treatment and research. He earned his medical degree and doctorate from Wuhan University and received international training as a Visiting Scholar at the German Cancer Research Center, Heidelberg University, and MD Anderson Cancer Center in the United States. His clinical and research interests focus on tumor radiotherapy and the tumor immune microenvironment, with particular emphasis on how irradiation influences tumor biology, radiotherapy efficacy, and radiation-induced lung injury, including the role of fibroblasts and tumor interstitial fibrosis in treatment outcomes. Prof. Yao has secured major research funding from the National Natural Science Foundation of China, the Hubei Natural Science Foundation, and multiple institutional projects, while building collaborations with world-leading cancer research centers in Germany and the United States. He has published extensively in high-impact journals such as Nature Communications, The EMBO Journal, Journal of Clinical Oncology, Cancer Medicine, Histopathology, Nano Letters, and Frontiers in Immunology, in addition to co-editing oncology volumes and holding software copyrights. Recognized with numerous national, provincial, and institutional awards for his contributions to research, clinical practice, and mentorship, Prof. Yao serves on national and provincial oncology committees, is a member of ASCO and ESMO, and continues to mentor doctoral and master’s students, making lasting contributions to oncology education, clinical innovation, and cancer research.

Profile: Orcid

Featured publications

  • Zhang, H., Chen, L., Li, L., Liu, Y., Das, B., Zhai, S., Tan, J., Jiang, Y., Turco, S., Yao, Y., & Frishman, D. (2025). Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning. NPJ Precision Oncology, 9(1), 76.

  • Dong, Y., Khan, L., & Yao, Y. (2024). Immunological features of EGFR-mutant NSCLC and clinical practice. Journal of the National Cancer Center, 4(4), 289–298.

  • Yi, L., Wen, Y., Xiao, M., Yuan, J., Ke, X., Zhang, X., Khan, L., Song, Q., & Yao, Y. (2024). The proportion of tumour stroma predicts response to immune checkpoint inhibitor plus chemotherapy in stage IIIB–IV NSCLC. Histopathology, 85(2), 295–309.

  • Yao, Y., Shen, Y., Yao, J. C., & Zuo, X. (2024). Editorial: New advancement in tumor microenvironment remodeling and cancer therapy. Frontiers in Cell and Developmental Biology, 12, 1384567.

  • Li, Y., Chen, J., Wang, B., Xu, Z., Wu, C., Ma, J., Song, Q., Geng, Q., Yu, J., Pei, H., & Yao, Y. (2023). FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resistance Updates, 67, 100926.

  • Yao, Y., Chu, Y., & Xu, B. (2019). Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Medicine, 8(2), 554–563.

Prof. Kang-Ho Choi | Nanotherapy Awards | Best Researcher Award

Published on by ScienceFather

Prof. Kang-Ho Choi | Nanotherapy Awards | Best Researcher Award

Prof. Kang-Ho Choi, Chonnam National University Medical School and Hospital, South Korea

Dr. Kang-ho Choi is an esteemed Associate Professor in the Department of Neurology at Chonnam National University Hospital, Gwangju, Korea. He earned his M.D. from Chonnam National University Medical School in 2005, followed by a Ph.D. from the same institution in 2011. Dr. Choi completed extensive postgraduate training, including fellowships at Hanyang University Medical Center and Bristol University. His research and clinical expertise focus on neurology, with notable contributions in stroke and neurodegenerative diseases. Dr. Choi has received numerous awards for his research and clinical excellence, including multiple “Best Investigator” and “Best Poster Presentation” awards. He is a member of various professional organizations, including the Korean Neurological Association and the American Heart Association/American Stroke Association.

Professional Profile:

Scopus

Evaluation of Kangho Choi, M.D., Ph.D. for the Best Researcher Award

Summary of Suitability for Award:

Dr. Kangho Choi is a distinguished researcher in the field of neurology with an impressive track record of achievements that make him a highly suitable candidate for the Best Researcher Award

🎓Education:

Dr. Kang-ho Choi completed his medical education at Chonnam National University Medical School in Gwangju, Korea, where he earned his M.D. degree from March 1999 to February 2005. He continued his academic journey at Chonnam National University Graduate School, obtaining his Master’s degree (M.S.) from March 2006 to February 2008, and later his Ph.D. from March 2009 to February 2011.

🏢Work Experience:

Dr. Kang-ho Choi has held several key positions in his career. Since November 2016, he has been serving as an Associate Professor in the Department of Neurology at Chonnam National University Hospital in Gwangju, Korea. Prior to this role, he was an Assistant Professor in the same department from March 2011 to October 2016. Dr. Choi completed his Clinical Fellowship at Chonnam National University Hospital from March 2010 to February 2011, and also undertook Research Fellowships at Hanyang University Medical Center in Seoul, Korea, from November 2010 to December 2010, and at the School of Clinical Sciences, Bristol University in the United Kingdom, from March 2013 to June 2013. His foundational training includes a Residency in Neurology at Chonnam National University Hospital from March 2006 to February 2010 and a Medical Internship at the same institution from March 2005 to February 2006.

🏅Awards:

Dr. Kang-ho Choi has received numerous prestigious awards throughout his career, reflecting his significant contributions to neurology. He was honored with the Best Investigator Award from Chonnam National University Hospital in December 2019 and May 2022. Additionally, he received the Break-through of the Year award from KHIDI of Korea in December 2017 and from the NRF of Korea in December 2020. In July 2017, he earned the Young Investigator Award at the Hwasun Biomedical Workshop. Dr. Choi’s excellence in research presentations is highlighted by multiple Best Poster Presentation Awards, including those from the ICSU & ICAS Joint Conference in September 2016, the ICSU 2018 & 1st AKJSC Joint Conference in September 2018, Stroke Update 2023 & 11th JKJSC in November 2023, and APSC 2023 in December 2023. His accolades also include the Best Presentation Award at the 35th Conference of KNA in November 2016, the Best Article award at the Annual Meeting of the Korean Neurological Association in October 2009, and the Best Doctor of the Year award from Chonnam National University Hospital in February 2010. Earlier in his career, he was recognized as the Best Resident of the Year by The Korean Intern Resident Association in February 2007.

Publication Top Notes:

  • Focused Magnetic Stimulation for Motor Recovery After Stroke
  • Treatment of Ischemic Stroke by Atorvastatin-Loaded PEGylated Liposome
  • Secular Trends in Outcomes and Impact of Novel Oral Anticoagulants in Atrial Fibrillation-Related Acute Ischemic Stroke
  • Contemporary Statistics of Acute Ischemic Stroke and Transient Ischemic Attack in 2021: Insights From the CRCS-K-NIH Registry
  • Erratum: Corrigendum to “D-dimer to Fibrinogen Ratio Predicts Early Neurological Deterioration in Ischemic Stroke with Atrial Fibrillation”